PRTA News and Press, Prothena Corporation plc From 08/06/25

Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy 1-3 Novo Nordisk successfully completed a Phase 2 trial with coramitug and is expected to initiate a Phase 3 program in 2025 Prothena to earn a clinical mileston...

2025-08-04 16:54:54 ET More on Prothena Roche And Prothena: Why Moving On Makes Sense Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place Prothena Q2 2025 Earnings Preview Prothena to lay off 63% of workforce, revises full year ...

Net cash used in operating and investing activities was $46.4 million in the second quarter and net cash used in operating and investing activities was $99.8 million for the first six months of 2025; quarter-end cash and restricted cash position was $372.3 million Prothena expects to convene ...

Kyndryl Holdings Inc. (KD) is expected to report $0.25 for Q1 2026 Bruker Corporation (BRKR) is expected to report $0.33 for Q2 2025 Vornado Realty Trust (VNO) is expected to report $0.53 for Q2 2025 Diamondback Energy Inc. (FANG) is expected to report $2.63 for Q2 2025 Freightcar...

Prothena Corporation plc (PRTA) is expected to report $-1.11 for Q2 2025

2025-08-03 18:45:28 ET Prothena Corporation plc (PRTA) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 5.74%. The average open to low on the day of earnings was -5.59%. The average open ...

2025-08-03 18:40:29 ET Prothena Corporation plc (PRTA) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in PRTA stock price following earnings has averaged ±3.91% , with a median of 3.64%....

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2025 financial results on Monday, Aug...

2025-06-26 23:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2025-06-18 16:19:40 ET More on Prothena Roche And Prothena: Why Moving On Makes Sense Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place Prothena jumps as partner Roche to advance Parkinson's drug into late-stage studies Read...